Ortiz-Salvador JM, et al. - Because secukinumab is the first-class interleukin 17A monoclonal antibody which has shown an outstanding safety and efficacy profile in phase 3 studies, researchers assessed the efficacy of secukinumab in daily clinical practice and the clinical and epidemiologic features of secukinumab treated patients in clinical settings. The study sample consisted of 158 adult patients with moderate-to-severe plaque psoriasis from 12 hospitals in Spain during January-December 2016. For this investigation, study participants were treated with secukinumab and prospectively followed at 12-week intervals for 52 weeks. According to this multicenter prospective observational study, secukinumab is a safe treatment with similar efficacy rates to those found in its phase 3 studies. These rates last up to a year from the beginning of therapy.